4-Repeat Tauopathy Neuroimaging Initiative - Cycle 2

a study on Corticobasal Degeneration Corticobasal Syndrome Progressive Supranuclear Palsy Frontotemporal Dementia Primary Progressive Aphasia Progressive Nonfluent Aphasia

Summary

Eligibility
for people ages 40-80 (full criteria)
Healthy Volunteers
healthy people welcome
Location
at San Diego, California and other locations
Dates
study started
estimated completion
Principal Investigator
by Irene Litvan, MD
Headshot of Irene Litvan
Irene Litvan

Description

Summary

The goal of this study is to identify the most reliable methods of analysis for tracking CBD, PSP, and o/vPSP over time. The results from this study may be used in the future to calculate statistical power for clinical drug trials. The study will also provide information about the relative value of novel imaging techniques for diagnosis, as well as the value of imaging techniques versus testing of blood, urine, and cerebrospinal fluid (CSF) 'biomarkers'.

Official Title

The Four-Repeat Tauopathy Neuroimaging Initiative

Keywords

Corticobasal Degeneration (CBD), Corticobasal Syndrome (CBS), Cortical-basal Ganglionic Degeneration (CBGD), Progressive Supranuclear Palsy (PSP), Nonfluent Variant Primary Progressive Aphasia (nfvPPA), Oligosymptomatic/Variant Progressive Supranuclear Palsy (o/vPSP), CBD, CBS, CBGD, PSP, nfvPPA, oPSP, vPSP, o/vPSP, Corticobasal Degeneration, Corticobasal Syndrome, Cortocal-basal Ganglionic Degeneration, Progressive Supranuclear Palsy, Nonfluent Variant Primary Progressive Aphasia, Oligosymptomatic Progressive Supranuclear Palsy, Variant Progressive Supranuclear Palsy, Biomarker, Neuroimaging, MRI, PET, Tau, Oculomotor, Retinal Imaging, Paralysis, Aphasia, Supranuclear Palsy, Progressive, Aphasia, Primary Progressive, Pick Disease of the Brain, Frontotemporal Dementia, Tauopathies, PSP & CBD

Eligibility

You can join if…

Open to people ages 40-80

  • No known history of neurological disease, or meet criteria for one of the following: Corticobasal Syndrome or Degeneration (CBS or CBD); Progressive Supranuclear Palsy (PSP); or Oligo- or Variant- Progressive Supranuclear Palsy (o/vPSP)
  • Needs a reliable study partner who has frequent contact with the participant, who is available to provide information about the participant, and who can accompany the participant to research visits as needed
  • Must be willing and able to undergo testing procedures, which include longitudinal follow-up visits
  • Must be able to walk five steps with minimal assistance

You CAN'T join if...

  • Significant neurological disease other than CBD, PSP, or a variant PSP syndrome.
  • Presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, or metal fragments or metal objects in the eyes, skin, or body
  • In the site investigator's opinion, inability to complete sufficient key study procedures, or some other equivalent assessment of impairment

Locations

  • University of California, San Diego (UCSD) accepting new patients
    San Diego California 92037 United States
  • University of California, San Francisco (UCSF) accepting new patients
    San Francisco California 94158 United States

Lead Scientist at UCSD

  • Irene Litvan, MD
    Dr. Irene Litvan is the Tasch Endowed Professor of Neurology and Director of the Parkinson and Other Movement Disorder Center at the University of California, San Diego (UCSD).

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
University of California, San Francisco
ID
NCT02966145
Study Type
Observational
Participants
Expecting 232 study participants
Last Updated
Contact us about this trial